title: A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
abstract: OBJECTIVE
  To determine the activity and tolerability of weekly docetaxel in patients with platinum-resistant mullerian origin tumors.
  
  
  METHODS
  Patients with persistent disease, or those recurring less than 6 months after receiving platinum-containing therapy, were eligible for this phase II study. Docetaxel was initially administered at a dose of 40 mg/m(2) on days 1, 8, and 15, with a cycle length of 28 days. This starting dose was subsequently reduced to 30 mg/m(2) due to toxicity. Dexamethasone prophylaxis was administered at a dose of 4 mg PO every 12 hours for 3 doses, starting 12 hours before each dose of docetaxel.
  
  
  RESULTS
  Thirty-two patients were enrolled, with a median age of 59 years. The majority of patients received a median of 3 prior regimens, with 45% of the study group having received 4 or more prior regimens. The overall response rate in 29 evaluable patients was 6.9%, with no complete responses. Seventeen percent of patients experienced stable disease. Dose reduction or delay was required in 10 of the first 22 patients enrolled, prompting a reduction in the starting dose to 30 mg/m(2). Hematologic toxicity was generally tolerable, and no patient experienced febrile neutropenia. Non-hematologic toxicity was generally grade 1 in nature, although a combination of multiple low grade toxicities occurring in an individual patient oftentimes mandated dose reduction.
  
  
  CONCLUSIONS
  Weekly docetaxel demonstrated modest activity in a heavily pre-treated, platinum-resistant population. A starting docetaxel dose of 30 mg/m(2) would be reasonable for future studies exploring the utility of weekly dosing in less heavily pre-treated patients.
authors.affiliation: Dana-Farber/Harvard Cancer Center Program in Gynecologic Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Berkenblit
authors.forename: Michael V
authors.initials: MV
authors.lastname: Seiden
authors.forename: Ursula A
authors.initials: UA
authors.lastname: Matulonis
authors.forename: Richard T
authors.initials: RT
authors.lastname: Penson
authors.forename: Carolyn N
authors.initials: CN
authors.lastname: Krasner
authors.forename: Maria
authors.initials: M
authors.lastname: Roche
authors.forename: Lisa
authors.initials: L
authors.lastname: Mezzetti
authors.forename: Tina
authors.initials: T
authors.lastname: Atkinson
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Cannistra
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D043823:Taxoids; D000077143:Docetaxel